Greg Miknis

Find an error

Name:
Organization: Colorado State University
Department: Colorado Center for Drug Discovery
Title:
Co-reporter:Greg F. Miknis, Sarah J. Stevens, Luke E. Smith, David A. Ostrov, Mair E.A. Churchill
Bioorganic & Medicinal Chemistry Letters 2015 Volume 25(Issue 4) pp:963-968
Publication Date(Web):15 February 2015
DOI:10.1016/j.bmcl.2014.11.067
The histone chaperone anti-silencing function 1 (Asf1) has emerged as a promising target for therapeutic intervention for multiple cancers (Cell2006, 127, 458). Asf1 is involved in the packaging of the eukaryotic genome into chromatin, which is essential for normal growth, development, and differentiation, as this regulates all nuclear processes that use DNA as a substrate. Starting from a collection of HTS leads, we identified a series of N-acyl hydrazones as novel inhibitors of the Asf–histone H3/H4 interaction. These compounds represent the first example of inhibitors capable of disrupting the Asf1–H3/H4 complex.
Benzoic acid, 4-[[(acetylamino)acetyl]amino]-
Benzoic acid, 4-(benzoylamino)-, (4-pyridinylmethylene)hydrazide
N-[4-(Hydrazinocarbonyl)phenyl]benzamide
4-Pentanamidobenzoic acid
Benzoic acid,4-[(4-methoxybenzoyl)amino]-, hydrazide
3-Methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)benzaldehyde oxalate
4-Quinolinecarboxamide, N,N-diethyl-2-(4-methoxyphenyl)-
(E)-N'-(3-bromo-4-hydroxy-5-methoxybenzylidene)isonicotinohydrazide
Phenol, 4-(2-aminoethyl)-2-bromo-6-methoxy-
3-(2-Morpholinoethoxy)benzaldehyde